PSPaul Schadler

Paul Schadler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul Schadler has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Leithner

    Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria

    3 shared publications
  • Martin Helmut Stradner

    Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    3 shared publications
  • Bettina Thauerer

    Ludwig Boltzmann Institute for Arthritis and Rehabilitation, 5760 Saalfelden, Austria

    2 shared publications
  • Bibiane Steinecker-Frohnwieser

    Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Saalfelden, Austria

    2 shared publications
  • Birgit Lohberger

    Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria

    2 shared publications
  • Martin Faschingbauer

    Department of Orthopaedic Surgery, University Hospital Ulm, Ulm, Germany

    2 shared publications

Latest Publications

  • Sex as an effect modifier in the association between postoperative troponin and mortality after coronary artery bypass grafting: a retrospective cohort study

    by Nikolaus Schreiber, Selina Sartori, Stephanie Fida, Paul Schadler, Jakob Pannold, Igor Knez, Sami Mouritane, Michael Schörghuber, Christoph Klivinyi, Sonja Fruhwald

  • Open Access

    The Association of Blood Biomarkers and Body Mass Index in Knee Osteoarthritis: A Cross-Sectional Study

    by Paul Schadler, Birgit Lohberger, Bettina Thauerer, Martin Faschingbauer, Werner Kullich, Martin Helmut Stradner, Andreas Leithner, Valentin Ritschl, Maisa Omara, Bibiane Steinecker-Frohnwieser

    Objective: Despite massive efforts, there are no diagnostic blood biomarkers for knee osteoarthritis (KOA). This study investigated several candidate diagnostic biomarkers and the metabolic phenotype in end-stage KOA in the context of obesity. Design: In this cross-sectional study, adult patients undergoing knee arthroplasty were enrolled and KOA severity was assessed using the Lequesne index. Blood biomarkers with an important role in obesity, the metabolic syndrome, or KOA (oxidized form of low-density lipoprotein [oxLDL], advanced glycation end product [AGE], soluble AGE receptor [sRAGE], fatty acid binding protein 4 [FABP4], phospholipase A2 group IIA [PLA2G2A], fibroblast growth factor 23 [FGF-23], ghrelin, leptin, and resistin) were measured using enzyme-linked immunosorbent assay (ELISA; n = 70) or Luminex technique (subgroup of n = 35). H1-NMR spectroscopy was used for the quantification of metabolite levels (subgroup of n = 31). The hip-knee-ankle angle was assessed. Multivariable and multivariate regression analysis was used to examine the relationship of biomarkers with body mass index (BMI) and KOA severity in complete case and multiple imputation analysis. Results: While most of the investigated biomarkers were not associated with KOA severity, FABP4 and leptin were found to correlate with BMI and gender. Resistin was associated with Lequesne index in complete case analysis. Using a targeted metabolomics approach, BMI-dependent changes in the metabolome were hardly visible. Conclusions: Our findings confirm studies on FABP4, leptin, and resistin with regard to obesity and the metabolic syndrome. There was no association of the investigated biomarkers with KOA severity, most likely due to the patient selection (end-stage KOA patients). Based on this absence of BMI-dependent changes in the metabolome, we might assume that BMI is not correlated with KOA severity in this specific patient group.


  • Fatty Acid–Binding Protein 4 (FABP4) Is Associated with Cartilage Thickness in End-Stage Knee Osteoarthritis

    by Paul Schadler, Birgit Lohberger, Bettina Thauerer, Martin Faschingbauer, Werner Kullich, Martin Helmut Stradner, Rusmir Husic, Andreas Leithner, Bibiane Steinecker-Frohnwieser

    There is no single blood biomarker for the staging of knee osteoarthritis (KOA). The purpose of this study was to assess the relationship of obesity, serum biomarkers, the hip-knee-ankle angle (HKAA) with sonographic cartilage thickness. We conducted a cross-sectional study of n = 33 patients undergoing knee arthroplasty. Body mass index (BMI) was recorded, and patients were grouped based on BMI. Serum blood samples were collected, and the following biomarkers were measured using the ELISA technique (subgroup of n = 23): oxidized low-density lipoprotein (oxLDL), soluble receptor for advanced glycation end-products (sRAGE), fatty acid–binding protein 4 (FABP4), membrane-bound phospholipase A2 (PLA2G2A). The HKAA was analyzed on full-length limb standing x-ray images. Cartilage thickness was assessed on ultrasound images. Multivariable regression analysis was performed to account for confounding. After adjusting for age, gender, and HKAA, obese patients had thicker medial femoral cartilage (β = 0.165, P = 0.041). Furthermore, lateral cartilage thickness was negatively correlated with FABP4 level after adjusting for of age, gender, BMI, and HKAA (β = −0.006, P = 0.001). Confirming previous studies, after adjustment, FABP4 level was associated with a higher BMI group (β = 42.99, P < 0.001). None of the other markers (oxLDL, PLA2G2A, and sRAGE) was associated with BMI or cartilage thickness. Our results indicate that BMI has a weak, positive association with cartilage thickness in end-stage KOA patients. FABP4 levels were negatively associated with cartilage thickness. While our study is limited by a small sample size, these results further highlight the role of FABP4 as promising biomarkers of burden of disease in KOA.


  • The Effect of Body Mass Index and Metformin on Matrix Gene Expression in Arthritic Primary Human Chondrocytes

    by Paul Schadler, Birgit Lohberger, Nicole Stündl, Martin Helmut Stradner, Dietmar Glänzer, Patrick Sadoghi, Andreas Leithner, Bibiane Steinecker-Frohnwieser

    Obesity is a known risk factor for knee osteoarthritis (OA). Diabetes has been associated with progression of OA and metformin is the first-line treatment in type 2 diabetes. The effect of the body mass index (BMI) and metformin on the expression of certain matrix genes in human chondrocytes is unclear. The purpose of this study was to investigate the effect of BMI and metformin on the expression of matrix genes in primary human chondrocytes. Adult female patients undergoing knee arthroplasty for end-stage OA were enrolled. Primary chondrocytes were cultivated and stimulated with metformin. Matrix gene expression was analyzed using polymerase chain reaction. Clinical data were used in multivariable regression models to assess the influence of BMI and metformin stimulation on gene expression. A total of 14 patients were analyzed. BMI was a predictor of increased expression in ADAMTS5 (β = −0.11, P = 0.03). Metformin slightly reduced expression in ADAMTS5 (β = 0.34, P = 0.04), HIF-1a (β = 0.39, P = 0.04), IL4 (β = 0.30, P = 0.02), MMP1 (β = 0.47, P < 0.01), and SOX9 (β = 0.37, P = 0.03). The hip-knee-ankle angle and proton pump inhibitors (PPIs) intake were associated with reduced SOX9 expression (β = 0.23, P < 0.01; β = 2.39, P < 0.01). Higher C-reactive protein (CRP) levels were associated with increased MMP1 expression (β = −0.16, P = 0.02). We found that BMI exerts a destructive effect via induction of ADAMTS5. Metformin reduced the expression of catabolic genes ADAMTS5 and MMP1 and might play a role in disease prevention. Limb malalignment and PPI intake was associated with a reduced expression of SOX9, and higher CRP levels correlated with increased MMP1 expression, indicating a destructive process.